THE ECOSYSTEM
INTEROPERABILITY
IMMUTABILITY
PRIVACY & INTEGRITY BY DESIGN
TRACEABILITY
PORTABILITY
TRANSPARENCY
Clinical trials take too long, cost too much, and are operationally inefficient. Data, documents, and processes are often duplicated, inaccurate, and cannot be shared or integrated easily which aids in additional time and cost of trials.
At Cellgen, we are developing a universal clinical trial ecosystem that allows life science companies to transform and automate their business processes into the cloud, while also achieving real-time interoperability and analytics of all data, documents, and processes.
This transformation will help drive faster, smarter, and better-informed decisions by enabling predictive and analytic models that generate actionable business intelligence to improve key clinical trial success drivers including issues with compliance protocol, informed consent and recruitment, and drug accountability. This ecosystem can improve trial workflow and traceability, enabling more timely and accurate status reports, timely payments to investigational sites and CROs, and improved budget tracking.
The Cellgen Ecosystem will allow the industry the ability to share data, documents, and processes in ways that reduce the administrative burden, time, and effort of protocol adherence while also ensuring integrity, privacy and security. Our ecosystem will enforce the major requirements of NIH-funded, multi-site clinical trials starting with an automated audit trail to ensure data privacy, data integrity, protocol violation detection, protocol amendments, and timely reporting of adverse events. Cellgen is designing a secure, efficient, and robust infrastructure that not only enforces global regulatory obligations but also ensures an increased level of security and optimization of cost.
OUR MISSION
To help pharmaceutical companies bring drugs to market faster and cheaper by developing and maintaining a universal, clinical trial ecosystem focused on digital transformation and automation of internal business processes. The incorporation of real-time interoperability and analytics will facilitate single sources of truth across disparate systems and for data, documents, and processes within the ecosystem. These efficiencies will significantly reduce drug time to market and increase return on investment